Metastatic Prostate Cancer
This e-course will comprise three presentations that provide comprehensive state-of-the-art information on currently available therapies for hormone-naïve prostate cancer (HNPC) and castration-resistant prostate cancer (CRPC).
| Organiser | European School of Urology (ESU) |
|---|---|
| CME | 1.00 |
| Duration | Approx. 60 minutes |
The therapies will include androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPI), chemotherapy, radioligand, and poly (ADP-ribose) polymerase (PARP) inhibitors.
The e-course aims to enable participants in optimising treatment combinations and sequences in metastatic prostate cancer at all disease stages.
Speakers:
Prof. B. Tombal (BE)
Dr. C. Thibault (FR)
Prof. Dr. C. Gratzke (DE)